Two Years of Treatment With Dehydroepiandrosterone Does Not Improve Insulin Secretion, Insulin Action, or Postprandial Glucose Turnover in Elderly Men or Women (original) (raw)
Metabolism| March 01 2007
1Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic College of Medicine, Rochester, Minnesota
Search for other works by this author on:
2Department of Electronics and Informatics, University of Padova, Padova, Italy
Search for other works by this author on:
2Department of Electronics and Informatics, University of Padova, Padova, Italy
Search for other works by this author on:
1Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic College of Medicine, Rochester, Minnesota
Search for other works by this author on:
1Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic College of Medicine, Rochester, Minnesota
Search for other works by this author on:
1Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic College of Medicine, Rochester, Minnesota
Search for other works by this author on:
1Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic College of Medicine, Rochester, Minnesota
Search for other works by this author on:
3Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota
Search for other works by this author on:
2Department of Electronics and Informatics, University of Padova, Padova, Italy
Search for other works by this author on:
2Department of Electronics and Informatics, University of Padova, Padova, Italy
Search for other works by this author on:
1Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic College of Medicine, Rochester, Minnesota
Search for other works by this author on:
Address correspondence and reprint requests to Robert A. Rizza, MD, Mayo Clinic College of Medicine, 200 1st St. SW, Rm. 5-194 Joseph, Rochester, MN 55905. E-mail: [email protected]
Diabetes 2007;56(3):753–766
Connected Content
A correction has been published: Errata
Citation
Rita Basu, Chiara Dalla Man, Marco Campioni, Ananda Basu, K. Sree Nair, Michael D. Jensen, Sundeep Khosla, George Klee, Gianna Toffolo, Claudio Cobelli, Robert A. Rizza; Two Years of Treatment With Dehydroepiandrosterone Does Not Improve Insulin Secretion, Insulin Action, or Postprandial Glucose Turnover in Elderly Men or Women. _Diabetes 1 March 2007; 56 (3): 753–766. https://doi.org/10.2337/db06-1504
Download citation file:
To determine if dehydroepiandrosterone (DHEA) replacement improves insulin secretion, insulin action, and/or postprandial glucose metabolism, 112 elderly subjects with relative DHEA deficiency ingested a labeled mixed meal and underwent a frequently sampled intravenous glucose tolerance test before and after 2 years of either DHEA or placebo. Despite restoring DHEA sulphate concentrations to values observed in young men and women, the changes over time in fasting and postprandial glucose concentrations, meal appearance, glucose disposal, and endogenous glucose production were identical to those observed after 2 years of placebo. The change over time in postmeal and intravenous glucose tolerance test insulin and C-peptide concentrations did not differ in men treated with DHEA or placebo. In contrast, postmeal and intravenous glucose tolerance test change over time in insulin and C-peptide concentrations were greater (P < 0.05) in women after DHEA than after placebo. However, since DHEA tended to decrease insulin action, the change over time in disposition indexes did not differ between DHEA- and placebo-treated women, indicating that the slight increase in insulin secretion was a compensatory response to a slight decrease in insulin action. We conclude that 2 years of replacement of DHEA in elderly men and women does not improve insulin secretion, insulin action, or the pattern of postprandial glucose metabolism.
R.A.R. has served on an advisory board for Merck, Novo Nordisk, Takeda, Mankind, and Eli Lilly; has acted as a consultant for Abbot, Takeda, Symphony Capital, and Eli Lilly; and holds stock in Diobex.
Clinical trial reg. no. NCT00254371, clinicaltrials.gov.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
You do not currently have access to this content.
Sign in
Pay-Per-View Access
$40.00